Global Patent Index - EP 1406631 A4

EP 1406631 A4 20050323 - DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON

Title (en)

DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON

Title (de)

DOPAMIN-REZEPTOR-LIGANDEN UND DARAUF BERUHENDE THERAPEUTISCHE VERFAHREN

Title (fr)

LIGANDS DES RECEPTEURS DE DOPAMINE ET PROCEDES THERAPEUTIQUES CORRESPONDANTS

Publication

EP 1406631 A4 20050323 (EN)

Application

EP 02744349 A 20020613

Priority

  • US 0218914 W 20020613
  • US 29744501 P 20010613

Abstract (en)

[origin: WO02100350A2] The present invention relates to compounds designed as ligands (<i>e</i>.<i>g</i>., agonists, antagonists, and partial agonists) for dopamine receptors (<i>e</i>.<i>g</i>., D1, D2, D3, D4, and D5), and in particular, the D1, D2, and D3 dopamine receptors. The present invention also relates to methods for rationally designing these compounds and to therapeutic methods of using these compounds.

[origin: WO02100350A2] The present invention relates to compounds designed as ligands (e.g., agonists, antagonists, and partial agonists) for dopamine receptors (e.g., D1, D2, D3, D4, and D5), and in particular, the D1, D2, and D3 dopamine receptors. The present invention also relates to methods for rationally designing these compounds and to therapeutic methods of using these compounds.

IPC 1-7

A61K 31/495; A61K 31/50; A61P 25/00; C07D 241/36; C07D 241/02; C07D 471/04

IPC 8 full level

A61K 31/495 (2006.01); A61P 25/00 (2006.01); C07D 471/04 (2006.01)

CPC (source: EP)

A61K 31/495 (2013.01); A61P 25/00 (2017.12); C07D 471/04 (2013.01)

Citation (search report)

  • [X] WO 9740015 A1 19971030 - NEUROGEN CORP [US], et al
  • [X] US 3647791 A 19720307 - ROSSI ALBERTO, et al
  • [X] WO 9604250 A1 19960215 - PFIZER [US], et al
  • [X] WO 9420497 A1 19940915 - MERCK SHARP & DOHME [GB]
  • [X] I. BOYFIELD ET AL.: "n-(substituted-phenyl)piperazines:", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 11, 1996, GB, pages 1227 - 32, XP004134859
  • [X] V.ARUNA RAO: "agents acting on the central nervous system. XIII:", JOURNAL OF MEDICINAL CHEMISTRY., vol. 13, no. 3, 1970, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 516 - 22, XP002292998
  • [X] G.B. SINGH ET AL.: "antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)2,3,4,4a,5,6-hexahydro-1(h)-pyrazino(1,2-a)quinoline hydrochloride", EXPERIENTIA., vol. 29, no. 12, 15 December 1973 (1973-12-15), CHBIRKHAUSER VERLAG. BASEL., pages 1529 - 30, XP002292999
  • [X] G.B. SINGH ET AL.: "pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a5,6,hexahydro-1h-pyrazino(1,2-a)quinoline hydrochloride", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 28, no. 9, 1978, DEEDITIO CANTOR. AULENDORF., pages 1641 - 4, XP002293000
  • See references of WO 02100350A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02100350 A2 20021219; WO 02100350 A3 20030522; CA 2450315 A1 20021219; EP 1406631 A2 20040414; EP 1406631 A4 20050323

DOCDB simple family (application)

US 0218914 W 20020613; CA 2450315 A 20020613; EP 02744349 A 20020613